Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2)...

Area of Science:

• Neuroscience
• Molecular Biology
• Drug Discovery

Background:

• Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are a significant genetic cause of Parkinson's Disease (PD).
• LRRK2 activity and dimerization are implicated in PD pathogenesis.
• Previous work developed allosteric peptide inhibitors targeting LRRK2 dimerization.

Purpose of the Study:

• To design and evaluate doubly constrained peptides inhibiting C-terminal of Roc (COR)-COR mediated LRRK2 dimerization.
• To assess the cell permeability, binding affinity, and inhibitory effects of these novel peptides on LRRK2 activity and downstream effects.

Main Methods:

• Design of doubly constrained peptides targeting the LRRK2 COR-COR dimer interface.
• Assessment of peptide cell permeability and binding to wild-type and mutant LRRK2.
• Inhibition assays for LRRK2 dimerization and kinase activity.
• Evaluation of LRRK2-mediated neuronal apoptosis in cellular models.
• Comparison of cellular localization with ATP-competitive inhibitors.

Main Results:

• Doubly constrained peptides were cell-permeant and bound to LRRK2.
• These peptides effectively inhibited LRRK2 dimerization and kinase activity.
• The peptides demonstrated inhibition of LRRK2-mediated neuronal apoptosis.
• Unlike ATP-competitive inhibitors, these peptides did not cause LRRK2 mislocalization.

Conclusions:

• COR-mediated dimerization is crucial for LRRK2 activity.
• Doubly constrained peptides represent a promising therapeutic approach for PD by inhibiting LRRK2 dimerization.
• This strategy offers an alternative to ATP-competitive inhibitors, avoiding detrimental cellular effects.